Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma

NCT00600054 is registered in ClinicalTrials.gov with YM BioSciences as lead sponsor.

NCT NCT00600054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00600054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma
Lead sponsor
YM BioSciences
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
December 31, 2010
Enrollment
44 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse pontine gliomas